Pharmaron Shares Surge Over 3% as Nine-Month Net Profit Rises 9.3%; Lab Services Growth Outlook Remains Highly Certain

Stock News10-30 14:10

Pharmaron (03759) shares rose more than 3%, reaching HK$27.96 as of press time, up 3.86%, with a turnover of HK$159 million.

On the news front, Pharmaron recently disclosed its third-quarter results. Huaxi Securities noted that Pharmaron's third-quarter performance slightly exceeded expectations. The company achieved operating revenue of RMB 12.00 billion for the first three quarters of 2026, up 19.0% year-on-year; net profit attributable to shareholders of RMB 1.247 billion, up 9.3% year-on-year; non-GAAP net profit of RMB 1.181 billion, up 14.2% year-on-year; and adjusted non-IFRS net profit attributable to shareholders of RMB 1.496 billion, up 21.97% year-on-year.

The brokerage further noted that Pharmaron's laboratory services segment generated revenue of RMB 2.59 billion in the third quarter of 2026, up 17.5% year-on-year, continuing its trend of marginal improvement. Given that new orders signed in the first three quarters of 2026 grew by more than 25%, the future earnings growth of the company's laboratory services business is highly certain.

The CDMO business generated revenue of RMB 1.22 billion in the third quarter of 2026, up 30.1% year-on-year. With the continued advancement of the company's small-molecule CDMO pipeline, Pharmaron expects demand for late-clinical and commercial-stage projects to maintain strong growth. Considering that new orders signed for the CDMO business grew by more than 40%, the company's performance is expected to continue its high-speed growth trajectory in the coming years.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1174579841?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-10-30 14:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1174579841","market":"nz","top_or_hot":-1,"title":"Pharmaron Shares Surge Over 3% as Nine-Month Net Profit Rises 9.3%; Lab Services Growth Outlook Remains Highly Certain","media":"Stock News","content":"<p>Pharmaron (03759) shares rose more than 3%, reaching HK$27.96 as of press time, up 3.86%, with a turnover of HK$159 million.<br><br>On the news front, Pharmaron recently disclosed its third-quarter results. Huaxi Securities noted that Pharmaron's third-quarter performance slightly exceeded expectations. The company achieved operating revenue of RMB 12.00 billion for the first three quarters of 2026, up 19.0% year-on-year; net profit attributable to shareholders of RMB 1.247 billion, up 9.3% year-on-year; non-GAAP net profit of RMB 1.181 billion, up 14.2% year-on-year; and adjusted non-IFRS net profit attributable to shareholders of RMB 1.496 billion, up 21.97% year-on-year.<br><br>The brokerage further noted that Pharmaron's laboratory services segment generated revenue of RMB 2.59 billion in the third quarter of 2026, up 17.5% year-on-year, continuing its trend of marginal improvement. Given that new orders signed in the first three quarters of 2026 grew by more than 25%, the future earnings growth of the company's laboratory services business is highly certain.<br><br>The CDMO business generated revenue of RMB 1.22 billion in the third quarter of 2026, up 30.1% year-on-year. With the continued advancement of the company's small-molecule CDMO pipeline, Pharmaron expects demand for late-clinical and commercial-stage projects to maintain strong growth. Considering that new orders signed for the CDMO business grew by more than 40%, the company's performance is expected to continue its high-speed growth trajectory in the coming years.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pharmaron Shares Surge Over 3% as Nine-Month Net Profit Rises 9.3%; Lab Services Growth Outlook Remains Highly Certain</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPharmaron Shares Surge Over 3% as Nine-Month Net Profit Rises 9.3%; Lab Services Growth Outlook Remains Highly Certain\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-10-30 14:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Pharmaron (03759) shares rose more than 3%, reaching HK$27.96 as of press time, up 3.86%, with a turnover of HK$159 million.<br><br>On the news front, Pharmaron recently disclosed its third-quarter results. Huaxi Securities noted that Pharmaron's third-quarter performance slightly exceeded expectations. The company achieved operating revenue of RMB 12.00 billion for the first three quarters of 2026, up 19.0% year-on-year; net profit attributable to shareholders of RMB 1.247 billion, up 9.3% year-on-year; non-GAAP net profit of RMB 1.181 billion, up 14.2% year-on-year; and adjusted non-IFRS net profit attributable to shareholders of RMB 1.496 billion, up 21.97% year-on-year.<br><br>The brokerage further noted that Pharmaron's laboratory services segment generated revenue of RMB 2.59 billion in the third quarter of 2026, up 17.5% year-on-year, continuing its trend of marginal improvement. Given that new orders signed in the first three quarters of 2026 grew by more than 25%, the future earnings growth of the company's laboratory services business is highly certain.<br><br>The CDMO business generated revenue of RMB 1.22 billion in the third quarter of 2026, up 30.1% year-on-year. With the continued advancement of the company's small-molecule CDMO pipeline, Pharmaron expects demand for late-clinical and commercial-stage projects to maintain strong growth. Considering that new orders signed for the CDMO business grew by more than 40%, the company's performance is expected to continue its high-speed growth trajectory in the coming years.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03759","symbol_name":"康龙化成","start_time":0,"source_url":"","article_id":"1174579841","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1174579841","pubTimestamp":1793340625,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Pharmaron (03759) shares rose more than 3%, reaching HK$27.96 as of press time, up 3.86%, with a turnover of HK$159 million.On the news front, Pharmaron recently disclosed its third-quarter results....","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"300759":"康龙化成","03759":"康龙化成","BK1141":"生命科学工具和服务","KCAI":"KraneShares China Alpha Index ETF","BK1576":"医药外包概念","VXUS":"国际股票ETF-Vanguard","BK0216":"研究试验","BK4588":"碎股","BK4585":"ETF&股票定投概念"},"translate_title":"康龙化成九个月净利润增长9.3%，股价飙升逾3%；实验室服务增长前景仍然高度确定","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300759":1,"03759":1,"KCAI":1,"VXUS":1},"content_text":"Pharmaron (03759) shares rose more than 3%, reaching HK$27.96 as of press time, up 3.86%, with a turnover of HK$159 million.On the news front, Pharmaron recently disclosed its third-quarter results. Huaxi Securities noted that Pharmaron's third-quarter performance slightly exceeded expectations. The company achieved operating revenue of RMB 12.00 billion for the first three quarters of 2026, up 19.0% year-on-year; net profit attributable to shareholders of RMB 1.247 billion, up 9.3% year-on-year; non-GAAP net profit of RMB 1.181 billion, up 14.2% year-on-year; and adjusted non-IFRS net profit attributable to shareholders of RMB 1.496 billion, up 21.97% year-on-year.The brokerage further noted that Pharmaron's laboratory services segment generated revenue of RMB 2.59 billion in the third quarter of 2026, up 17.5% year-on-year, continuing its trend of marginal improvement. Given that new orders signed in the first three quarters of 2026 grew by more than 25%, the future earnings growth of the company's laboratory services business is highly certain.The CDMO business generated revenue of RMB 1.22 billion in the third quarter of 2026, up 30.1% year-on-year. With the continued advancement of the company's small-molecule CDMO pipeline, Pharmaron expects demand for late-clinical and commercial-stage projects to maintain strong growth. Considering that new orders signed for the CDMO business grew by more than 40%, the company's performance is expected to continue its high-speed growth trajectory in the coming years.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.1","shortVersion":"4.52.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1174579841","isCrawlerRequest":true}